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ess: philip.pearson@noSummary Exhaled carbon monoxide (eCO) is a potential non-invasive marker of
airway inflammation. We have investigated the cross-sectional and longitudinal
relationship between eCO and lung function and bronchial reactivity in 69 adults
with atopic asthma, in the course of participation in a 6-week randomised placebo-
controlled trial of vitamin E supplementation. At baseline, there was no cross-
sectional association between absolute eCO levels and either forced expiratory
volume (FEV1), forced vital capacity (FVC) or bronchial reactivity. However, in the
longitudinal analysis within the placebo group, a rise in mean eCO was significantly
associated with improvement in bronchial reactivity (change in eCO (parts per
million) per natural log unit change in bronchial hyperreactivity 0.498, 95%
confidence interval 0.071 to 0.924, P ¼ 0:024). These findings suggest that, contrary
to previous data, there is no cross-sectional relationship between eCO and lung
function or bronchial reactivity, but that there may be a longitudinal trend with
bronchial reactivity that is worth further investigation.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Exhaled carbon monoxide (eCO) has been identified
as a potential non-invasive marker of airway
inflammation.1,2 Carbon monoxide is produced by
heme oxygenase-1 from heme,3,4 particularly in
response to oxidative stress, and eCO levels are
raised in adults with asthma.5,6 To date, however,
studies have found no clear evidence of associationElsevier Ltd. All rights reserv
969.
ttingham.ac.ukbetween eCO and lung function, as assessed by
both spirometry in adults and children,7–10 or
bronchial reactivity to methacholine (MCh) in
children.9 There are no studies of the association
of eCO and bronchial reactivity in adults with
asthma, and no longitudinal assessments of the
relationship between change in eCO and change in
forced expiratory volume in 1 s (FEV1) or bronchial
reactivity have been reported in participants with
asthma in the stable state.
We have therefore used data from a randomised
placebo-controlled trial of vitamin E supplementa-
tion in participants with stable asthma11 to exploreed.
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reactivity.Methods and materials
The analysis was carried out using data from a
randomised placebo-controlled trial of vitamin E
supplementation in participants with stable asth-
ma, which has been reported elsewhere.11 Briefly,
we enrolled patients aged 18–60 with physician-
diagnosed asthma, who were using at least one
dose of inhaled corticosteroid (ICS) per day; had
bronchial reactivity to o12.25 mmol MCh sufficient
to cause a 20% fall in FEV1 (PD20);
12 and were atopic
(defined as at least one allergen skin test response
(Dermatophagoides pteronyssinus, cat fur and grass
pollen) 2mm greater than control). All were self-
reported non-smokers with less than a 10 pack-year
history of smoking. Participants were studied at
randomisation and after 6 weeks, when spirometry,
bronchial reactivity, skin prick testing and eCO
were measured. Bronchial reactivity to MCh was
measured by the Yan method,12 and the PD20 values
log transformed for all analyses; change in PD20
being expressed in terms of doubling doses (DD).
FEV1 and forced vital capacity (FVC) were mea-
sured in litres using a Vitalograph 2120 spirometer
(Vitalograph, Buckingham, UK), taking the higher of
two successive measurements within 200ml for
FEV1, and the best of three technically satisfactory
measures for FVC. eCO was measured with a
Bedfont Micro Smokerlyzer (Bedfont Scientific Ltd,Table 1 Baseline characteristics of participants.
Number of participants
Age in years: mean (SD)
Sex: number (%)
Weight (kg): mean (SD)
Body mass index: mean (SD)
Duration of asthma in years: mean (SD)
Daily inhaled steroid dose (beclomethasone equivalent): m
(range)
Number on long-acting b2-agonists (number on salmeterol
number on formoterol)
FEV1 (l); mean (SD)
Predicted FEV1 (%): mean (SD)
FVC (l): mean (SD)
Baseline PD20: geometric mean (geometric SD)
FEV1: forced expiratory volume in 1 s.
FVC: forced vital capacity
Beclomethasone equivalence defined as 1mcg beclomethasonRochester, England), following a previously de-
scribed method13 to allow alveolar air sampling,
the result being expressed in parts per million
(ppm). The test was repeated to ensure consistency
and because previous research has reported that
the second reading can be significantly higher.14 All
study visits took place at the same time of the day
in each individual if was possible, after abstaining
from short-acting bronchodilator inhalers for 4 h,
long-acting bronchodilators for 12 h, and antihista-
mines for 24 h. Participants were asked to avoid
environmental smoke for 12 h before assessment.
All regular asthma medications were continued
unchanged. Participants experiencing clinical ex-
acerbation of asthma were treated as considered
appropriate by their supervising physician, return-
ing to their regular pre-exacerbation medication
use as soon as possible. Ethics approval was granted
by the Local Research Ethics Committee at Notting-
ham City Hospital.
Since it has been noted previously that eCO
increases on repeated measurements,13 we con-
ducted a cross-sectional analysis of the mean of
two eCO measurements at visit 215 against bron-
chial reactivity, FEV1 and FVC; the mean being
assumed to allow for inter-observation variability.
Longitudinal assessments within the placebo group
investigated the relationship between change in
mean eCO15 and change in bronchial reactivity and
FEV1 and FVC. A paired-samples t-test was used to
analyse change in eCO from first to second
measurement. For the longitudinal analysis, we
considered only the placebo group participants
completing the study per protocol (i.e. with noAll participants Placebo group
72 37
47.9 (8.9) 47.5 (9.4)
33 male (45.8%) 18 male (48.6%)
74.2 (17.0) 76.7 (19.5)
26.8 (7.6) 28.0 (9.6)
26.3 (14.1) 28.0 (13.7)
edian 400 (100–2000) 400 (200–1000)
; 19 (14; 5) 12 (7; 5)
2.51 (0.66) 2.53 (0.71)
77.1 (16.3) 76.5 (15.5)
3.67 (0.88) 3.71 (0.94)
0.77 (4.55) 0.69 (4.53)
e ¼ 1mcg budesonide ¼ 0.5mcg fluticasone.
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P. Pearson et al.1294increase or decrease in asthma treatment). Linear
regression was used to investigate the magnitude of
change in eCO against DD change, adjusting for
age, sex, height, and pack years smoked as a priori
confounders.
Statistical assessment was carried out with the
Statistical Package for the Social Sciences (SPSS
Inc., Chicago, USA).Results
The treatment and placebo groups were similar at
baseline in terms of age, regular drug use, PD20 and
lung function; baseline data are summarised in
Table 1. Of the 72 participants, 69 provided full
data at baseline. The second eCO measurement
was significantly higher than the first (mean (SD):
first reading 1.8 (1.1) ppm; second reading 2.1 (1.3)
ppm; P ¼ 0:028).
Of the 37 participants in the placebo group, 29
had paired data available to calculate change in
mean eCO. For these participants, the mean FEV1
and FVC at baseline were 2.40 (SD 0.63) litres and
3.64 (SD 0.94) litres, and at completion of the study
these values were 2.38 (SD 0.61) litres and 3.59 (SD
0.91) litres respectively.
At baseline, there was no cross-sectional associa-
tion between absolute eCO levels and either FEV1,
FVC, bronchial reactivity or peak flow variability.
However, in the longitudinal analysis of the placebo
group, a rise in mean eCO was significantly
associated with improvement in bronchial reactiv-
ity (change in eCO per natural log unit change in
bronchial hyperreactivity 0.498 (95% confidenceChange in exhaled carbon monoxide
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Figure 1 Scatter plot of log change in MCh dose against
change in exhaled carbon monoxide. Change in bronchial
reactivity is expressed as MCh doubling dose change.
Carbon monoxide is measured in parts per million.
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a change in FEV1 or FVC (Table 2; Fig. 1).Discussion
This study has assessed the cross-sectional relation-
ship between exhaled carbon monoxide (eCO) and
bronchial reactivity in adults with asthma, and
measured eCO longitudinally in stable asthma. The
cross-sectional analysis was consistent with a
previous study in hospitalised patients8 demon-
strating that eCO was not correlated with FEV1. A
recent cross-sectional study in asthmatic patients16
found that eCO rose after histamine challenge and
was inversely associated with histamine PD20. This
conflicts with our findings and requires explanation.
It may be that differences in the participants,
equipment or environment may have contributed
to differences in outcome. For example, all our
participants were taking at least one dose of ICS,
which may have blunted any response. In addition,
no measurement of cotinine was made, so we are
unable to determine the extent to which our
observed carbon monoxide levels might have been
influenced by exposure to environmental tobacco
smoke.
However, our study also suggests that over time,
a decrease in bronchial reactivity (i.e. an improve-
ment) was associated with an increase in mean
eCO, which is unexpected. We know of no other
longitudinal data looking at this relationship.
Previous data have suggested an inverse association
between change in lung function and eCO, but have
been limited to recovery from exacerbations (serial
peak expiratory flow measurements over 21 days)7
or in response to antigen challenge17 (serial FEV1
over 20 h), rather than measurements of bronchial
reactivity. One possible explanation for our data is
that eCO, produced by inducible heme oxygenase,
is acting as an immunomodulatory agent, as
demonstrated in an animal model,18 or alterna-
tively as an antioxidant,3 which is consumed during
periods of oxidative stress, the level rising on
improvement due to reduced consumption in the
airways.
These findings are a secondary outcome of a
clinical trial, and could, therefore, represent
either a false negative (cross-sectional analysis)
or a false positive (longitudinal analysis). In
particular, it is common for participants in the
placebo arm of a clinical trial to improve due to
better adherence or closer monitoring, which
might explain an improvement in bronchial respon-
siveness in the placebo group. However, this doesnot explain the observed inverse relationship
between eCO and bronchial responsiveness, which
is novel. However, their findings are potentially
important primarily because they suggest that,
while a single eCO measurement may be of little
clinical use in asthma or as an indirect marker for
bronchial activity, a change in eCO may be used as a
surrogate marker of change in bronchial hyperreac-
tivity. If replicated elsewhere, this latter finding
may in turn be useful in clinical studies where it is
desirable to have frequent measurements or where
it is not feasible to bring participants to a central
unit for formal testing. Future work in this area
should include a larger, longitudinal study to look at
variability in eCO and include measurements of
eCO, carbon dioxide and nitric oxide simulta-
neously, which has been performed in response to
allergen challenge,19 but not repeatedly over time.
In summary, eCO was not cross-sectionally
associated with bronchial reactivity or lung func-
tion in this study, but increased eCO was associated
with improved bronchial reactivity. eCO therefore
shows potential as a non-invasive marker of change
in bronchial reactivity.Acknowledgement
This study was funded by the National Asthma
Campaign (now Asthma UK).References
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